Clinical factors influencing retreatment with anti-PD-(L)1 therapies after treatment in early-stage cancers: a modified Delphi consensus study by Christos Chouaïd, Lajos Pusztai, Federico Cappuzzo, Phillip Parente, Robert Jones, Vernon K Sondak, Masayoshi Nagata, Raquel Aguiar-Ibáñez, Yosuke Hirasawa, Ryuichi Mizuno, Smita Kothari, Carmel Spiteri, Alexander Sun, Chris Elder, Masaru Ishida, Seung Hyeun Lee, David Okonji, Bhavesh Shah, Dominihemberg Ferreira, Andrea Lauer, Amrit Kaliasethi, Carol Kao, Jan McKendrick

Get full text

Eosinophils as a predictive marker of treatment-related adverse events in mRCC patients treated with first-line immune-checkpoint inhibitor combination therapy by Tatsushi Kawada, Satoshi Katayama, Takafumi Yanagisawa, Keiichiro Mori, Wataru Fukuokaya, Kazumasa Komura, Takuya Tsujino, Ryoichi Maenosono, Kiyoshi Takahara, Takuhisa Nukaya, Lan Inoki, Shingo Toyoda, Takeshi Hashimoto, Yosuke Hirasawa, Kohei Edamura, Tomoko Kobayashi, Kensuke Bekku, Shingo Nishimura, Takehiro Iwata, Takuya Sadahira, Yusuke Tominaga, Tomoaki Yamanoi, Kasumi Yoshinaga, Kazuma Tsuboi, Yasuyuki Kobayashi, Atsushi Takamoto, Kyohei Kurose, Takahiro Kimura, Haruhito Azuma, Ryoichi Shiroki, Kazutoshi Fujita, Yoshio Ohno, Motoo Araki, On behalf of JK-FOOT study group

Get full text